|Elimination half-life||24.3 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||460.522 g·mol−1|
|3D model (JSmol)|
Abediterol (INN; development codes AZD-0548 and LAS 100977) is a once-daily experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is currently under development by the Spanish pharmaceutical company Almirall and is in Phase II clinical trials.
|This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.|